NASDAQ:ECOR

electroCore (ECOR) Stock Price, News & Analysis

$5.76
+0.11 (+1.95%)
(As of 04/26/2024 ET)
Today's Range
$5.61
$6.02
50-Day Range
$5.51
$7.03
52-Week Range
$3.83
$8.08
Volume
17,001 shs
Average Volume
8,847 shs
Market Capitalization
$34.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

electroCore MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
73.6% Upside
$10.00 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.59) to ($0.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.73 out of 5 stars

Medical Sector

425th out of 913 stocks

Electromedical Equipment Industry

8th out of 19 stocks

ECOR stock logo

About electroCore Stock (NASDAQ:ECOR)

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

ECOR Stock Price History

ECOR Stock News Headlines

electroCore, Inc. (ECOR)
Protect Yourself While There’s Still Time …
The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.
electroCore Expands Intellectual Property Portfolio
Protect Yourself While There’s Still Time …
The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.
Q4 2023 electroCore, Inc. Earnings Call
ElectroCore Q4 2023 Earnings Preview
Here's what to expect from electroCore's earnings
Ecora Res. Share Chat
Ecora Resources PLC ECOR
electroCore Expands Intellectual Property Portfolio
See More Headlines
Receive ECOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for electroCore and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
4/26/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:ECOR
Fax
N/A
Employees
68
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+73.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,830,000.00
Net Margins
-117.49%
Pretax Margin
-118.65%

Debt

Sales & Book Value

Annual Sales
$16.03 million
Book Value
$1.24 per share

Miscellaneous

Free Float
5,214,000
Market Cap
$34.56 million
Optionable
Not Optionable
Beta
0.91
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives


ECOR Stock Analysis - Frequently Asked Questions

Should I buy or sell electroCore stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for electroCore in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ECOR shares.
View ECOR analyst ratings
or view top-rated stocks.

What is electroCore's stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for electroCore's shares. Their ECOR share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 73.6% from the stock's current price.
View analysts price targets for ECOR
or view top-rated stocks among Wall Street analysts.

How have ECOR shares performed in 2024?

electroCore's stock was trading at $5.95 at the start of the year. Since then, ECOR shares have decreased by 3.2% and is now trading at $5.76.
View the best growth stocks for 2024 here
.

Are investors shorting electroCore?

electroCore saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 8,800 shares, a drop of 12.9% from the March 31st total of 10,100 shares. Based on an average daily trading volume, of 10,400 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.2% of the company's stock are short sold.
View electroCore's Short Interest
.

When is electroCore's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ECOR earnings forecast
.

How were electroCore's earnings last quarter?

electroCore, Inc. (NASDAQ:ECOR) issued its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by $0.06. The firm earned $5.19 million during the quarter, compared to the consensus estimate of $5.23 million. electroCore had a negative net margin of 117.49% and a negative trailing twelve-month return on equity of 201.47%. During the same period in the prior year, the business earned ($1.22) EPS.

When did electroCore's stock split?

Shares of electroCore reverse split on the morning of Tuesday, February 14th 2023. The 1-15 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of electroCore own?

Based on aggregate information from My MarketBeat watchlists, some companies that other electroCore investors own include T2 Biosystems (TTOO), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Acasti Pharma (ACST), Onconova Therapeutics (ONTX) and OPKO Health (OPK).

When did electroCore IPO?

electroCore (ECOR) raised $64 million in an IPO on Friday, June 22nd 2018. The company issued 4,300,000 shares at $14.00-$16.00 per share. Evercore ISI and JMP Securities acted as the underwriters for the IPO and BTIG was co-manager.

Who are electroCore's major shareholders?

electroCore's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include International Assets Investment Management LLC (0.88%) and PFG Investments LLC (0.30%). Insiders that own company stock include Brian M Posner, Daniel S Goldberger, John P Gandolfo, Joseph P Errico, Thomas J Errico, Thomas J Errico and Trevor J Moody.
View institutional ownership trends
.

How do I buy shares of electroCore?

Shares of ECOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ECOR) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners